I'll research FISV before writing the preview. Let me pull recent filings, transcripts, and news.Note: Fiserv now trades under ticker FI (formerly FISV). Let me read the most recent transcript and gather recent news/price action.Let me get recent price action and news around the stock, plus check for an Investor Day and any recent developments.The price series cut off in March. Let me get the recent months and search broader news including the May Investor Day.Key developments found: a CEO departure and M&A interest in the debit network. Let me read those and get recent prices.Let me grab the year-ago Q2 2025 numbers as the comparison base and check the insider-buying note.# Fiserv (NASDAQ: FI) — Q2 2026 Earnings Preview
Note on the ticker: Fiserv trades as FI on NYSE (the old "FISV" symbol is retired). This preview covers what the market will be watching into tomorrow's print.
This is arguably the most consequential Fiserv report in years: it's the first quarter reported by new CEO Takis Georgakopoulos, it lands on the guided trough quarter for year-over-year revenue, it laps an extremely tough year-ago comp (Q2 2025 was +8% organic / $2.47 adj. EPS), and it comes with a live M&A catalyst (big-bank interest in Fiserv's debit network) hanging over the stock — all after a brutal ~70%+ drawdown.
Fiserv has gone from fintech darling to "show-me" story in about 18 months:
Takeaway: Sentiment is washed out, the CEO seat just turned over, and there's an unusual strategic optionality overhang. That combination makes the setup unusually binary.
On the Q1 2026 call (May), CFO Paul Todd was explicit that Q2 is the trough:
| Metric | 2026 Guide |
|---|---|
| Organic revenue growth | 1% – 3% (Merchant mid-single digits; Financial flat to slightly down) |
| Adjusted revenue growth | 1% – 3% |
| Adjusted EPS | $8.00 – $8.30 |
| Adjusted operating margin | ~34% (H1 31–32%, H2 35–36%, Q4 the peak) |
| Adjusted tax rate | 19% – 19.5% |
| Weighted avg. shares | ~530M |
| FCF conversion | ~90% of adj. net income |
| Year-end gross leverage | ~3.0x (was ~3.2x at Q1) |
Note the ~20% EPS reset: 2026's $8.00–$8.30 is well below 2025's ~$10.20 area — 2026 is explicitly a "transition year" absorbing investment spend, lapping nonrecurring revenue, and normalizing margins.
Q2 2026 laps Fiserv's last "old-model" strong quarter:
| Q2 2025 (year-ago base) | Result |
|---|---|
| Adjusted revenue | $5.20B, +8% |
| Organic revenue | +8% (Merchant +9%, Financial +7%) |
| Adjusted EPS | $2.47, +16% |
| Adjusted operating margin | 39.6% |
| Merchant / Financial op. margin | 34.6% / 48.7% |
Against that, Q2 2026 revenue will likely be down year over year and adjusted EPS meaningfully below $2.47. A modeled reference point: Q1 2026 printed adjusted revenue of $4.68B (-2.4%), organic -3.6%, margin 29.7%, and adjusted EPS of $1.79 — but that EPS included a ~$0.17 one-time tax benefit (11% Q1 tax rate), which reverses via higher tax rates in Q2–Q4. So watch for a below-the-line tax headwind in Q2 relative to a normalized ~19.5% rate.
1) The new CEO's tone and any "reset." Georgakopoulos's first call as CEO. The key question: does he reaffirm the $8.00–$8.30 EPS / 1–3% organic frame, or use his first quarter to rebase expectations (a classic new-CEO move)? Any change to the mid-single-digit-revenue / double-digit-EPS long-term algorithm laid out at the May Investor Day will move the stock more than the quarter itself.
2) The debit-network (STAR/Accel) situation. Expect analysts to press on the reported big-bank interest. Watch for any confirmation of a strategic review, portfolio/disposition commentary (Lyons had flagged "evaluating potential dispositions"), and the tension flagged by skeptics (e.g., William Blair): selling to large banks could alienate the community-bank/credit-union base that benefits from Durbin. Any hard data point here is a catalyst.
3) Clover — GPV and "clean" growth. Clover is the growth engine and the most-watched KPI. Reported Q2 growth will be depressed by peak hardware/nonrecurring comps, so focus on: GPV growth (guided 10–15% ex-gateway, ~12% ex-gateway in Q1), processing revenue tracking GPV, VAS attach (27% of Clover revenue, +18% in Q1), and traction in new verticals (PracticePay/healthcare, Professional Services), international (Brazil, TD Canada), and Clover Capital. The full-year Clover revenue guide is low double digits — management needs Q2 to keep that credible.
4) Financial Solutions — is the trough really the trough? This is the crux of the bear case. Watch core bank account attrition (down 2% y/y in Q1, still "above long-term target"), retention KPIs (Lyons cited high-impact incidents down ~60%, resolution time down 27%), and whether underlying volumes (debit, Zelle +18%, Finxact accounts +70%) support the "flat-ish clean base" narrative. Management needs to convince investors that H2 re-acceleration is contracted/visible, not hopeful.
5) Margins and capital allocation. Q2 margin will trough near the low-30s vs. 39.6% a year ago — investors want confidence in the H2 35–36% ramp and Project Elevate (AI-driven cost/revenue program) delivering. Also watch the buyback pace: Fiserv pulled way back to ~$200M / 3.3M shares in Q1 (vs. ~$2.2B/quarter in 2025) to hit ~3.0x leverage. Any change in repurchase posture given the depressed share price is notable.
Going in, Q2 is set up to be the ugliest optical quarter of the year (down revenue, ~20%-lower EPS, margin trough vs. a 39.6% year-ago comp) — and management pre-signaled all of it. Because the "bad" is largely known, the stock is more likely to trade on three forward-looking swing factors: (1) whether new CEO Georgakopoulos holds or resets the full-year frame, (2) any concrete update on a debit-network transaction, and (3) evidence that the Financial Solutions trough and Clover trajectory are genuinely inflecting toward the promised H2 re-acceleration. With shares near multi-year lows, washed-out sentiment, an activist present, and insiders buying, the risk/reward is unusually two-sided into the print.
This is a research summary for informational purposes, not investment advice. Consensus figures were not available in my sources; comparisons here are drawn from company guidance and prior filings.